January 16, 2020
ASKA Pharmaceutical said on January 14 that it has entered into an option agreement with a biotech originated from Kyoto University, KinoPharma, for an exclusive license to develop and commercialize the biotech’s investigational cervical dysplasia compound. Under the terms of...read more